A Double-Blind, Randomized, Placebo Controlled, Multi-Center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.

Trial Profile

A Double-Blind, Randomized, Placebo Controlled, Multi-Center Trial of Oseltamivir for the Seasonal Prophylaxis of Influenza in Immunocompromised Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Oseltamivir (Primary) ; Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 04 May 2016 Time frame for primary endpoint changed from 12 weeks to 112 days.
    • 30 Aug 2009 Results reported at the 14th Congress of the European Society for Organ Transplantation.
    • 20 May 2009 Actual number of patients (477) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top